GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (NYSE:ENOV) » Definitions » ROE %
中文

Enovis (Enovis) ROE % : 0.35% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Enovis ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Enovis's annualized net income for the quarter that ended in Dec. 2023 was $12 Mil. Enovis's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $3,429 Mil. Therefore, Enovis's annualized ROE % for the quarter that ended in Dec. 2023 was 0.35%.

The historical rank and industry rank for Enovis's ROE % or its related term are showing as below:

ENOV' s ROE % Range Over the Past 10 Years
Min: -15.72   Med: 2.95   Max: 13.85
Current: -0.97

During the past 13 years, Enovis's highest ROE % was 13.85%. The lowest was -15.72%. And the median was 2.95%.

ENOV's ROE % is ranked worse than
78.33% of 2954 companies
in the Industrial Products industry
Industry Median: 7.07 vs ENOV: -0.97

Enovis ROE % Historical Data

The historical data trend for Enovis's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis ROE % Chart

Enovis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.72 1.22 1.76 -0.33 -0.97

Enovis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.51 -2.71 -1.16 -0.33 0.35

Competitive Comparison of Enovis's ROE %

For the Specialty Industrial Machinery subindustry, Enovis's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enovis's ROE % Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Enovis's ROE % distribution charts can be found below:

* The bar in red indicates where Enovis's ROE % falls into.



Enovis ROE % Calculation

Enovis's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-33.261/( (3448.085+3418.392)/ 2 )
=-33.261/3433.2385
=-0.97 %

Enovis's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=11.856/( (3439.622+3418.392)/ 2 )
=11.856/3429.007
=0.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Enovis  (NYSE:ENOV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=11.856/3429.007
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(11.856 / 1820.08)*(1820.08 / 4455.1255)*(4455.1255 / 3429.007)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.65 %*0.4085*1.2992
=ROA %*Equity Multiplier
=0.27 %*1.2992
=0.35 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=11.856/3429.007
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (11.856 / 30.628) * (30.628 / -0.808) * (-0.808 / 1820.08) * (1820.08 / 4455.1255) * (4455.1255 / 3429.007)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.3871 * -37.9059 * -0.04 % * 0.4085 * 1.2992
=0.35 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Enovis ROE % Related Terms

Thank you for viewing the detailed overview of Enovis's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enovis (Enovis) Business Description

Traded in Other Exchanges
Address
2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.
Executives
John Kleckner officer: Principal Accounting Officer 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben) officer: SVP, Chief Financial Officer 2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota director 8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall director
Brady Shirley officer: EVP, Colfax, Pres. & CEO, DJO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang officer: SVP, Chief HR Officer C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy officer: SVP, General Counsel P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor officer: SVP??Strategy & Business Deve. DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola director, officer: President & CEO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix officer: SVP, Chief Financial Officer 2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz director 1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor director 3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda officer: ESAB President and SVP, Colfax 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts officer: Controller, PAO 100 MATSONFORD ROAD, RADNOR PA 19087